89 related articles for article (PubMed ID: 11575717)
21. Tresperimus (Laboratoires Fournier).
Elices MJ
Curr Opin Investig Drugs; 2001 Mar; 2(3):372-4. PubMed ID: 11575707
[TBL] [Abstract][Full Text] [Related]
22. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
23. Technology evaluation: Onyvax-P, Onyvax.
Doehn C; Böhmer T; Jocham D
Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
25. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
Schmitz G
Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical data on novel anticancer, antiangiogenesis drug.
Oncology (Williston Park); 1998 Sep; 12(9):1395. PubMed ID: 9778687
[No Abstract] [Full Text] [Related]
27. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors: from bench to clinic.
Paris M; Porcelloni M; Binaschi M; Fattori D
J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
[No Abstract] [Full Text] [Related]
29. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Newman S
Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
[TBL] [Abstract][Full Text] [Related]
30. Experimental models for the development of new medical treatments in prostate cancer.
Chauchereau A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S200-14. PubMed ID: 21943976
[No Abstract] [Full Text] [Related]
31. Ongoing phase II & III studies of the USA National Prostatic Cancer Project.
Elder JS; Gibbons RP
Prog Clin Biol Res; 1985; 185A():427-34. PubMed ID: 3898135
[No Abstract] [Full Text] [Related]
32. American Society of Clinical Oncology--41st annual meeting. Drug highlights II.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):534-6. PubMed ID: 15973556
[No Abstract] [Full Text] [Related]
33. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
34. Novel agents in colorectal cancer.
Erlichman C
Tumori; 2001; 87(1 Suppl 1):S9. PubMed ID: 11300041
[No Abstract] [Full Text] [Related]
35. American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.
Mason VL
IDrugs; 2010 Jun; 13(6):360-2. PubMed ID: 20506053
[TBL] [Abstract][Full Text] [Related]
36. Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development.
Lee DY; Staddon AP; Shabason JE; Sebro R
Cancer Med; 2019 Feb; 8(2):585-592. PubMed ID: 30632291
[TBL] [Abstract][Full Text] [Related]
37. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
Gelmon KA; Eisenhauer EA; Harris AL; Ratain MJ; Workman P
J Natl Cancer Inst; 1999 Aug; 91(15):1281-7. PubMed ID: 10433616
[No Abstract] [Full Text] [Related]
38. New anticancer agents.
Weiss GR; Burris HA; Eckardt JR; Fields S; Johnson R; O'Rourke T; Rodriguez GI; Rothenberg ML; Wall J
Cancer Chemother Biol Response Modif; 1993; 14():118-28. PubMed ID: 8312101
[No Abstract] [Full Text] [Related]
39. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
J Clin Pharmacol; 1994 Feb; 34(2):111-9. PubMed ID: 8163710
[No Abstract] [Full Text] [Related]
40. The development of anticancer agents.
Connors TA
Natl Med J India; 1997; 10(6):259-61. PubMed ID: 9481094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
